Mestag Therapeutics

Information for participants. Last reviewed: October 9, 2026.

Research shows Tertiary Lymphoid Structures (TLSs) in tumors improve patient outcomes and therapy responses across solid tumor types.

Applying fibroblasts’ newly recognized role as immune sentinels.

Lewandowska et al., AACR Annual Meeting 2024 - available on request

Lewandowska et al., Cancer Immunotherapy Keystone Symposia 2026 - available on request

Cambridge, UK, 27 September 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced that

Cambridge, UK, December 20, 2022 – Mestag Therapeutics (“Mestag”), an immunotherapy company harnessing new insights into fibroblast-immune interactions in

– Oversubscribed seed round supports the development of impactful medicines targeting activated fibroblast populations in inflammatory disease and cancer

Cambridge, UK, October 20, 2022 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, is pleased to

Mestag applies its core values to advance new science into patient-focused therapies.

Mestag develops cancer and inflammatory disease treatments by studying fibroblast-immune cell interactions.

Driving fibroblast-immune conversations in cancer and inflammatory diseases.

Mestag Therapeutics protects the privacy and security of personal data.

Mestag Therapeutics secures **$40 million** in funding to progress its **FAP-targeted bispecific antibody** into clinical trials. The company focuses on developing therapies for fibrotic diseases and cancer by targeting fibroblast activation protein (FAP). This funding supports preclinical development and early-stage testing of its lead candidate.

Mar 2026cambridgebiocapital.substack.comNews article

Mestag Therapeutics secures $40 million in funding to develop its novel cancer therapy. The company focuses on advancing treatments targeting cancer cells with precision. This investment supports further research and clinical progress in oncology.

Mar 2026Drug Discovery World (DDW)News article

Mestag Therapeutics secures $40 million in funding to advance its fibroblast-targeted immunotherapy into the first clinical trial. The biotech company develops drugs designed to modulate fibroblast activity, a key cellular target in fibrosis and tissue remodeling. This funding supports the transition from preclinical research to human testing.

Mar 2026thepharmaletter.comNews article

Mestag Therapeutics secures $40 million in financing, raising total committed funds to over $95 million. The company appoints a Chief Medical Officer and Chief Development Officer to advance clinical preparations. Leadership hires signal readiness for upcoming clinical trials.

Mar 2026Mestag TherapeuticsNews article